首页 | 本学科首页   官方微博 | 高级检索  
     

聚ADP核糖聚合酶-1及其抑制剂在肿瘤细胞中的研究进展
引用本文:周强. 聚ADP核糖聚合酶-1及其抑制剂在肿瘤细胞中的研究进展[J]. 中国肿瘤临床, 2011, 38(24): 1612-1615. DOI: 10.3969/i.issn.1000-8179.2011.24.035
作者姓名:周强
作者单位:四川省遂宁市中心医院肿瘤科 (四川省遂宁市629000)
摘    要:聚ADP核糖聚合酶-1(PARP-1)在DNA单链断裂的碱基切除修复中具有非常重要的作用,在人类多种肿瘤中过度表达且过度表达者预后较差。利用合成致死原理,对于因BRCA1或BRCA2基因突变而同源重组修复DNA双链断裂缺陷的肿瘤细胞,抑制其PARP-1活性将导致肿瘤细胞死亡。PARP抑制剂对于携带BRCA基因突变肿瘤患者具有一定的治疗作用,其临床应用价值已在多项临床试验中得到了证实。PARP-1可能会成为肿瘤治疗的重要靶点。 

关 键 词:聚ADP核糖聚合酶类   聚ADP核糖聚合酶类抑制剂   肿瘤
收稿时间:2011-08-08

Progress in the Research of Poly(ADP-ribose)Polymerase-1 and Its Inhibitors in Malignant Tumors
Qiang ZHOU. Progress in the Research of Poly(ADP-ribose)Polymerase-1 and Its Inhibitors in Malignant Tumors[J]. Chinese Journal of Clinical Oncology, 2011, 38(24): 1612-1615. DOI: 10.3969/i.issn.1000-8179.2011.24.035
Authors:Qiang ZHOU
Affiliation:Department of Oncology Suining Central Hospital, Suining 629000, China
Abstract:Poly ( ADP-ribose ) polymerase-1 ( PARP-1 ) has a vital role in base excision repair of single-strand DNA breakage, and its over-expression has often been observed in various human tumor types, which correlates with a poor outcome. PARP-1 inhibition has been exploited in the repair of double-strange DNA breakage through a synthetic lethal approach for killing tumor cells with defects. This process is done via homologous recombination, particularly in the context of BRCA1 or BRCA2 mutation. Many clinical trials have demonstrated the clinical application value of PARP inhibitors in the treatment of cancer with BRCA mutations. PARP-1 will be an important target of tumor therapy. 
Keywords:
本文献已被 万方数据 等数据库收录!
点击此处可从《中国肿瘤临床》浏览原始摘要信息
点击此处可从《中国肿瘤临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号